key: cord-0689999-havazib2
authors: Yamamoto, Shohei; Maeda, Kenji; Matsuda, Kouki; Tanaka, Akihito; Horii, Kumi; Okudera, Kaori; Takeuchi, Junko S; Mizoue, Tetsuya; Konishi, Maki; Ozeki, Mitsuru; Sugiyama, Haruhito; Aoyanagi, Nobuyoshi; Mitsuya, Hiroaki; Sugiura, Wataru; Ohmagari, Norio
title: COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study
date: 2021-12-24
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab1048
sha: 1a58f331e7adf74e84c4781f41b453e4440e90e4
doc_id: 689999
cord_uid: havazib2

BACKGROUND: While increasing coverage of effective vaccines against coronavirus disease 2019 (COVID-19), emergent variants raise concerns about breakthrough infection. Data are limited, however, whether breakthrough infection during the epidemic of the variant is ascribed to insufficient vaccine-induced immunogenicity. METHODS: We described incident COVID-19 in relation to the vaccination program among workers of a referral hospital in Tokyo. During the predominantly Delta epidemic, we followed 2,415 fully vaccinated staff (BNT162b2) for breakthrough infection and selected three matched controls. We measured post-vaccination neutralizing antibodies against the wild-type, Alpha (B.1.1.7), and Delta (B.1.617.2) strains using live viruses and anti-spike antibodies using quantitative assays, and compared them using the generalized estimating equation model between the two groups. RESULTS: No COVID-19 cases occurred 1–2 months after the vaccination program during the fourth epidemic wave in Japan, dominated by the Alpha variant, while 22 cases emerged 2–4 months after the vaccination program during the fifth wave, dominated by the Delta variant. In the vaccinated cohort, all 17 cases of breakthrough infection were mild or asymptomatic and had returned to work early. There was no measurable difference between cases and controls in post-vaccination neutralizing antibody titers against the wild-type, Alpha, and Delta, and anti-spike antibody titers, while neutralizing titers against the variants were considerably lower than those against the wild-type. CONCLUSIONS: Post-vaccination neutralizing antibody titers were not decreased among patients with breakthrough infection relative to their controls under the Delta variant rampage. The result points to the importance of infection control measures in the post-vaccination era, irrespective of immunogenicity profile.

Clinical trials show that the mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in lowering the risk of coronavirus disease [1, 2] . In countries with high coverage of vaccination programs, however, the number of COVID-19 patients has started growing, which has been attributed to the emergence of Variants of Concern, especially the Delta (B.1.617.2) variant [3, 4] , and the waning of vaccine efficacy over time [5, 6] .

Epidemiological evidence is scarce regarding the role of vaccine-induced immunogenicity against Variants of Concern. In a case-control study among vaccinated healthcare workers, patients with breakthrough infection during the epidemic of the Alpha (B.1.1.7) variant had significantly lower peri-infection neutralizing antibody titers than controls [7] . A similar result was reported from a Vietnamese study [8] on breakthrough infection during the epidemic of the Delta variant, which is more resistant to the current vaccines than the Alpha variant [9] .

In Japan, the vaccination program has started in mid-February 2021, initially among healthcare workers using the BNT162b2 mRNA vaccine (Pfizer-BioNTech). After that, Japan has been hit by the two large waves of the COVID-19 epidemic: the fourth wave (April and May 2021), dominated by the Alpha variant, and the fifth wave (from July to September), overwhelmed with the Delta variant [10] . During the fifth wave, we observed a surge of breakthrough infection among the staff of a large referral hospital in Tokyo, Japan, where post-vaccination serum was available. This has prompted us to examine whether the breakthrough infection was ascribed to a failure of vaccination to build immunity or waning antibody-immunity compounded by the emergence of 

National Center for Global Health and Medicine, Japan (NCGM), comprised of two hospitals and affiliated facilities, is a medical research center for specific areas, including infectious disease. As their mission, NCGM has played a major role in the care and research of COVID-19 since the early stage of the epidemic [11] and has accepted many severe COVD-19 patients. During the in-house vaccination program using COVID-19 mRNA-LNP BNT162b2 (Pfizer-BioNTech) from March through June 2021, more than 90% of the NCGM staff have received the two-dose vaccine.

In NCGM, a repeat serological study has been launched since July 2020 to monitor the spread of SARS-CoV-2 infection among the staff during the course of COVID-19 epidemic. As of October 2021, we have completed three surveys, in each of which we measured anti-SARS-CoV-2 nucleocapsid-(all surveys) and spike-(from the second survey onward) protein antibodies, stored serum samples at -80 ℃ , and collected COVID-19 related information (vaccination, occupational infection risk, infection prevention practices, etc.) via a questionnaire. The results of the first and second surveys have been reported elsewhere [12, 13] . Participants of the third survey, which was conducted in June 2021 after in-house vaccination program, formed the basis of the present casecontrol analysis. Of 3,072 workers invited to the third survey, 2,779 (90%) participated. Written informed consent was obtained from all participants, and the study procedure was approved by the NCGM ethics committee (the approved number: NCGM-G-003598).

We identified COVID-19 cases among the study participants against the COVID-19 patients records kept by the NCGM Hospital Infection Prevention and Control Unit, which provided information on data of diagnosis, diagnostic procedure, possible route of the infection (close contact), symptoms, hospitalization, and return to work for all cases; and virus strain and Ct values for those who were diagnosed at NCGM. For COVID-19 cases among non-participants, the above data were A c c e p t e d M a n u s c r i p t 7 anonymized and submitted to the study committee after the opt-out procedure (the approved number:

NCGM-S-004382).

We conducted a case-control study nested in a sub-cohort of vaccinated participants who donated serum. Of 2,456 participants who completed the two vaccination before the third survey, we sequentially excluded those with a history of PCR-confirmed COVID-19 (n=14) and those with positive results on a SARS-CoV-2 nucleocapsid-protein antibody test at any of the three surveys (n=27), leaving 2,415 participants. Of these, we identified 17 cases of breakthrough infection, which were defined as cases diagnosed at least 14 days after the second dose of vaccine by September 6, 2021. For each case, we randomly selected three un-infected controls from the sub-cohort while matching worksite, sex, age, the interval between the second vaccination and blood sampling, and the propensity score, which was created based on body mass index, occupational exposure risk of SARS-CoV-2, and several infection prevention/risk behaviors. The details of the case-control matching algorithm are described in Supplemental Text 1.

The neutralizing activity of serum of cases and selected controls was determined by quantifying the serum-mediated suppression of the cytopathic effect (CPE) of each SARS-CoV-2 strain in VeroE6 TMPRSS2 cells [14] . The obtaining routes of the cells and each virus are described in Supplemental Text 2. Each serum was 4-fold serially diluted in a culture medium. The diluted sera were incubated with 100 50% tissue culture infectious dose (TCID 50 ) of viruses at 37°C for 20 min (final serum dilution range of 1:20 to 1:4000), after which the serum-virus mixtures were inoculated to VeroE6 TMPRSS2 cells (1.0 × 10 4 /well) in 96-well plates. For SARS-CoV-2 strains used in these assays are as follows: a Wuhan, wild-type strain (SARS-CoV-2 05-2N , PANGO lineage B) [14] , an Alpha variant (SARS-CoV-2 QHN001 ), and a Delta variant (SARS-CoV-2 1734 ). After culturing the cells for three days, the levels of CPE observed in SARS-CoV-2-exposed cells were determined using the WST-8 assay employing Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). The serum dilution that A c c e p t e d M a n u s c r i p t 8 gave 50% inhibition of CPE was defined as the 50% neutralization titer (NT 50 ). Each serum was tested in duplicate, and the average value was used for analysis. The laboratory technicians were blinded to the case-control status.

We assessed anti-SARS-CoV-2 antibodies for all participants of the third survey and retrieved those data for the case-control subsets. We quantitatively measured antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein by using the AdviseDx SARS-CoV-2 IgG II assay (Abbott) (IgG) and Elecsys ® Anti-SARS-CoV-2 S RUO (Roche) (predominantly IgG, also IgA and IgM). The sensitivity and specificity were reported as 97.6% and 100% for the Abbott assay [15] , respectively, and 97.9% and 99.9% for the Roche assay [16] , respectively. We also qualitatively measured antibodies against SARS-CoV-2 nucleocapsid protein using the SARS-CoV-2

IgG assay (Abbott) and Elecsys ® Anti-SARS-CoV-2 RUO (Roche), and used these data to exclude those with possible infection in the past. The sensitivity and specificity were 100% and 99.9% for the Abbott assay [17] , respectively, and 99.5% and 99.8% for the Roche assay [18] , respectively.

We compared the characteristics between cases and matched controls using Mann-Whitney U test or Fisher's exact test. To examine the differences in antibody-mediated immune response after the second vaccination between cases and controls, we compared the log-transformed titers of neutralizing (wild-type, Alpha, and Delta) and anti-spike antibodies between two groups using a generalized estimating equation (GEE) with the group assignment (case or control) and robust variance estimator. Then, we back-transformed and presented these values in geometric mean titer (GMT) with 95% confidence intervals (CIs). To compare the inter-individual differences in neutralizing antibody titers against the wild-type, Alpha, and Delta strains, we used the Wilcoxon ranked-sign test with adjustment using the Bonferroni method for multiple tests. Statistical analysis was performed using Stata 17.0 (StataCorp LLC), and graphics were made by GraphPad Prism 9 (GraphPad Inc). All P values were 2-sided, and P < 0.05 was considered statistically significant. during the two months in the fifth wave (after the in-house vaccination program) was only slightly higher than that observed during the third wave (December 2020 to January 2021) (before the program) (5.2 per 1000 persons), while the number of cases in Tokyo during the fifth wave (n=133,989) was 3.5 times higher than that during the third wave (n=38,492).

Of 17 cases of breakthrough infection in the case-control analysis, 47% were men, the median age was 29 (interquartile range [IQR]: 25-44) years, and the median interval between the second COVID-19 vaccination and breakthrough infection was 111 (IQR: 98-123) days. Their major occupations were nurses (53%), allied healthcare professionals (24%), and doctors (18%), and more than half (59%) were at low occupational risk of SARS-CoV-2 infection. The majority (88-100%) showed good adherence to infection prevention practices. As regards risky behaviors on leisure, 18% reported having spent 30 minutes or more in the 3Cs (crowded places, close-contact settings, and confined and enclosed spaces) without mask, and 12% reported having dined in a group of five or more people for more than an hour. There was no significant difference in these figures between cases and controls ( Table 1) .

A c c e p t e d M a n u s c r i p t 10 All the breakthrough cases occurred independently in different timings and departments, and there was no evidence of the clustering of infection in the hospital. The suspected sources of breakthrough infection were contacting COVID-19 patients in the household (35%), those in the community (24%), and unknown (41%), while none were suspected of nosocomial infection. Data on the type of SARS-CoV-2 strains were available for only 5 cases, and all of those were the Delta variant. All patients, except one (asymptomatic), experienced only mild symptoms: fever (65%), sore throat (35%), cough (24%), nasal discharge (18%), and malaise (18%), and they have returned to work without hospitalization or special medical care (Table1). The detailed characteristics of each breakthrough infection case are described in Supplemental Table 1 .

The post-vaccination neutralizing antibody titers against the wild-type, Alpha, and Delta (median 62 days between the second vaccination and blood sampling) were not statistically different between breakthrough cases and their matched controls (Table 2 and Figure 3A-C) . The GEE predicted neutralizing antibody GMTs against the wild-type was 405 (95% confidence interval [CI], 327-501) for cases and 408 (95% CI, 320-520) for controls, and this predicted case-to-control ratio The neutralization titers against the Alpha and Delta variants were much lower than those against the wild-type (Figure 4) . Among cases, the GMT (95% CI) of neutralizing antibody was 116 (77-175), 123 (83-182), and 404 (321-508) for the Alpha and Delta variants and the wild-type, respectively (P <0.01 for each variant versus Wild-type). Similar results were obtained for controls.

Among the staff of a large referral hospital in Tokyo, a series of breakthrough infection have been documented during the largest COVID-19 epidemic wave, dominated by the Delta variant. In a case-control study nested within the cohort of vaccinated staff, post-vaccination neutralizing antibody titers did not materially differ between breakthrough infection cases and their matched controls.

In NCGM, the number of COVID-19 patients during the fifth wave (n=23, 2 to 5 months after in-house vaccination program) was slightly higher than that during the third wave (n=17, before the vaccination program) despite 3.5 times the number of cases recorded during the former period than the latter period in Tokyo as a whole [19] . The vaccine effectiveness against the Delta variant infection after 4 months was 53% in the U.S. [4] and 35.1% in Qatar [5] . It is clear that vaccination program alone cannot eliminate the risk of infection by the Delta variant. Still, we could reasonably infer that the program has contributed to the sizable reduction in the number of COVID-19 patients among the staff during the largest epidemic.

We confirmed that the breakthrough cases occurred independently in different timings and departments, showing no evidence of clustered infection in the hospital. This finding is consistent with our previous reports from the first and second serological surveys in NCGM before the vaccination program [12, 13] , suggesting that infection among the staff had occurred mainly outside the hospital (household, community, etc.). NCGM has adopted comprehensive measures against nosocomial infection since the early phase of the epidemic. The current data confirm the significant role of these measures to protect healthcare workers against the Delta variant infection. This finding contradicts with data from Israel [7] and Vietnam [8] , both showing significantly lower neutralizing antibody titers among those with breakthrough infection than controls. While the reason for the discrepant findings is not clear, it could be ascribed to the difference in the timing of blood sampling for antibody testing (peri-infection [7, 8] Neutralizing capacity against the Alpha and Delta variants in the serum of the vaccinated participants was much lower than that against the wild-type strain, irrespective of breakthrough infection. This finding agrees with a previous report [20] and is consistent with the decreased vaccine effect observed during the epidemic predominantly of the Variants of Concern [3] [4] [5] . More than 90% of NCGM-Toyama ward staff have completed the second dose of vaccine by mid-April 2021. Soon after, the fourth epidemic wave of COVID-19 attacked Japan, dominated by Alpha; however, no vaccinated staff suffered from COVID-19, confirming high vaccine effect against infection of the Alpha variant within 2 months of vaccination [4, 5] . Breakthrough infection in NCGM from July to August 2021 could be attributed to the subsequent waning of neutralizing capacity and the largest epidemic due to the highly vaccine-resistant Delta variant [9, 20] .

We found that all the COVID-19 patients who completed two-dose vaccination experienced no or only mild symptoms and had successfully returned to work, a finding compatible with the previous reports [5, 7, 8, 20] . These data support that vaccination contributes to the maintenance of hospital function by shortening sick leave due to COVID-19 of healthcare workers and facilitating their earlier return to work.

The present study has several strengths. Both cases and controls were derived from a welldefined cohort. We rigorously matched each case and control using the propensity score estimated by A c c e p t e d M a n u s c r i p t 13 several factors potentially associated with infection risk (including the occupational risk of infection and prevention practices). The blood samples for antibody assays were obtained before the infection.

We measured neutralizing antibody titers against the wild-type strain and two major variants using live viruses.

We also acknowledge study limitations. We measured antibody levels using samples obtained 5 to 10 weeks (median, 8 weeks) before the infection, which might have decreased at the time of infection due to the waning of antibodies over time. Nevertheless, we confirmed no evidence of the difference between cases and controls in the association of the duration of time between vaccination and blood sampling with neutralizing antibody titers (Supplementary Figure 1) , denying faster waning of antibodies among cases than among controls. Despite the robust study design and rigorous matching strategy, we cannot exclude the possibility of bias due to unmeasured factors, including contact with the infected patient prior to breakthrough infection (not available for controls).

All four cases of breakthrough infection among non-participants were employees of NCGM contracting companies (cleaning and restaurant), and they were older than COVID-19 patients included in the case-control analysis (median age: 53 vs. 29 years), reflecting the characteristics of non-participants. Data on virus type were available for only 5 cases (all Delta variants). However, the remaining cases of breakthrough infection were most likely due to the Delta variant, which accounted for more than 90% of sequenced COVID-19 samples in Japan during the fifth epidemic wave [10] .

In conclusion, post-vaccination neutralizing antibodies against the wild-type, Alpha, and Delta variants did not materially differ between healthcare workers who experienced breakthrough infection A c c e p t e d M a n u s c r i p t 19 a Occupational SARS-CoV-2 exposure risk was categorized as follows: low (those who were not engaged in COVID-19-related work), moderate (those who were engaged in COVID-19-related work without heavy exposure to the virus), and high (those who were heavily exposed to SARS-CoV-2).

b In each question of infection prevention practice, participants' responses were in a 4-point Likert scale: "always,"

"often," "seldom," and "not at all," with the first two response options were defined as good adherence to infection prevention practice. These P values represented the results of comparison between (always or often) vs. (seldom or not at all). c 3Cs = crowded places, close-contact settings, and confined and enclosed spaces.

A c c e p t e d M a n u s c r i p t 1 M a n u s c r i p t 2 Data are shown the observed geometric mean titers (GMT) of antibodies in cases and matched controls and the predicted GMT using a generalized estimating equation (GEE) with the group assignment (case or control) used as the predictor. Three controls matched to each case were randomly selected from the study cohort using the following matching variables: worksite, sex, the interval between the seconddose vaccination and blood sampling, age, and the propensity score, which was created based on body mass index, occupational exposure risk of SARS-CoV-2, use of public transportation, the frequency of experiences spending 30 minutes or more in the 3Cs (crowded places, close-contact settings, and confined and enclosed spaces) without mask, the frequency of experience having dined in a group of five or more people for more than an hour, and the adherence to 6 types of infection preventive behaviors (avoid 3Cs; keep social distance; wear mask; practice cough etiquette; not to touch eyes, nose, and mouth; and wash or sanitize hands).

95%CI: 95% confidence interval. 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Available at: https://outbreak.info/locationreports?loc=JPN&dark=true&selected=Delta&selected=Alpha&selected=Beta&selected=Ga mma

SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine

Seroprevalence of antibodies against SARS-CoV-2 in a large national hospital and affiliated facility in

Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan

Correlates of Neutralizing/SARS-CoV-2-S1-binding

Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. medRxiv (preprint)

Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups

Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2

Status of COVID-19 positive patients in Tokyo

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Anti-spike antibody (Abbott) Observed GMT (95% CI)

We thank Haruka Osawa, Mika Shichishima, Yumiko Kito, and Azusa Kamikawa for their contribution to data collection and the staff of the Laboratory Testing Department for their contribution to measuring antibody testing. 

Abbott Japan and Roche Diagnostics provided reagents for anti-spike antibody assays.

A c c e p t e d M a n u s c r i p t 15 A c c e p t e d M a n u s c r i p t